All Trials

A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic activating EGFR-mutant NSCLC progressing after prior third-generation EGFR TKI and platinum chemotherapy, or platinum-ineligible, receive ivonescimab, a bispecific PD-1/VEGF antibody, combined with either datopotamab deruxtecan, a TROP2-directed topoisomerase I ADC, or osimertinib. The study includes patients with ECOG 0–1 and measurable disease, allowing controlled/asymptomatic CNS disease.

ClinicalTrials.gov ID: NCT07535437

An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with ECOG 0–1 and advanced relapsed/refractory solid tumors after standard therapy; dose escalation includes broad solid tumors including primary CNS tumors, while expansion focuses on ovarian cancer, endometrial cancer, and cholangiocarcinoma. Treatment is PHST001, a humanized IgG4 anti-CD24 antibody intended to block CD24–Siglec-10 innate immune checkpoint signaling and enhance macrophage phagocytosis, given as monotherapy or with chemotherapy backbones such as paclitaxel, topotecan, doxorubicin, FOLFIRI, FOLFOX, or gemcitabine.

ClinicalTrials.gov ID: NCT06840886

An Early Phase 1 Trial to Assess Pharmacodynamic Effects of OMO-103 in Patients With Pancreatic Ductal Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic pancreatic ductal adenocarcinoma, ECOG 0–2, treatment-naïve or previously treated, receive two short-course IV doses of OMO-103 on days 1 and 8 with paired tumor biopsies. OMO-103 is an investigational cell-penetrating miniprotein that directly inhibits MYC signaling by disrupting MYC–MAX dimerization and MYC/MAX DNA binding.

ClinicalTrials.gov ID: NCT07089940

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Enrolling adults with previously untreated metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation, ECOG 0-1, and no prior systemic therapy for metastatic disease. Patients receive investigator’s choice of first-line mFOLFIRINOX or gemcitabine/nab-paclitaxel plus either placebo or INCB161734, an investigational oral selective KRAS G12D inhibitor targeting the switch II pocket to inhibit downstream signaling.

ClinicalTrials.gov ID: NCT07522073

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with progressive metastatic castration-resistant prostate adenocarcinoma, ECOG 0–1, generally after prior androgen receptor pathway inhibitor and often taxane therapy, excluding neuroendocrine/small-cell disease, CNS involvement, significant cardiovascular disease, and prior AR-PROTAC exposure. Participants receive oral AZD9750, an androgen receptor–degrading PROTAC, as monotherapy or combined with saruparib/AZD5305, a PARP1-selective inhibitor.

ClinicalTrials.gov ID: NCT07336446

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with previously untreated advanced unresectable or metastatic intermediate/high-grade soft tissue sarcoma receive physician-selected first-line systemic therapy plus oral extended-release metformin. Metformin is a biguanide with proposed anticancer activity via reduced insulin/IGF signaling and AMPK activation with downstream mTOR pathway inhibition.

ClinicalTrials.gov ID: NCT07291297

Study of Tegavivint, a Transducin Beta-like Protein 1 (TBL1) Inhibitor, With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label dose-escalation/expansion study for patients with relapsed or refractory osteosarcoma after intensive frontline chemotherapy, with measurable/evaluable disease or selected patients rendered NED after pulmonary metastasectomy. All patients receive IV tegavivint, a TBL1 inhibitor that disrupts TBL1–β-catenin interaction and suppresses Wnt/β-catenin signaling, plus IV gemcitabine in 21-day cycles.

ClinicalTrials.gov ID: NCT07144254

Phase II Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-response (REGIMEN-KS HIV)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with HIV-associated Kaposi sarcoma and persistent CD4 lymphopenia (CD4 ≤350 cells/mcL) despite virologically suppressed antiretroviral therapy, with measurable cutaneous disease and either treatment-naive or previously treated KS, receive intramuscular CYT107 weekly for up to 4 weeks with possible retreatment. CYT107 is investigational glycosylated recombinant human IL-7 intended to restore T-cell immunity via IL-7 receptor signaling and improve immune control of KSHV.

ClinicalTrials.gov ID: NCT07308886

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 small cell lung cancer, including previously treated recurrent/progressive SCLC and a cohort of treatment-naive extensive-stage SCLC after ≤1 cycle of platinum chemotherapy. Patients receive IV tarlatamab, a DLL3×CD3 bispecific T-cell engager, plus ZL-1310/zocilurtatug pelitecan, an investigational DLL3-targeted topoisomerase I ADC, with durvalumab anti–PD-L1 added in the first-line ES-SCLC triplet cohort.

ClinicalTrials.gov ID: NCT07531095

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated extensive-stage SCLC and ECOG 0–1 receive first-line YL201, an investigational B7-H3–directed antibody–drug conjugate with a topoisomerase I inhibitor payload, plus atezolizumab. The study is testing escalating/optimized YL201 doses with fixed-dose PD-L1 blockade, without platinum-etoposide chemotherapy.

ClinicalTrials.gov ID: NCT07407933